{"title": "PDF", "author": "PDF", "url": "https://www.medicasur.com.mx/pdf-revista/RMS143-AO01-PROTEGIDO.pdf", "hostname": "PDF", "description": "PDF", "sitename": "PDF", "date": "PDF", "id": "PDF", "license": "PDF", "body": "PDF", "comments": "PDF", "commentsbody": "PDF", "raw_text": "PDF", "text": "116 Rev Invest Med Sur Mex,  2014; 21 (3): 116-119Prote\u00ednas 14-3-3 y Tau como biomarcadores en  enfermedades neurodegenerativas.\nEstudio de las prote\u00ednas 14-3-3 y Tau\ncomo biomarcadores en pacientes con\nenfermedades neurodegenerativas de origen no\ndeterminado. Experiencia en el Laboratorio de\nPatolog\u00eda Cl\u00ednica de M\u00e9dica Sur\n* Laboratorio de Patolog\u00eda Cl\u00ednica, ** Departamento de Medicina Interna, *** Departamento de Neurolog\u00eda/Neurofisiolog\u00eda, M\u00e9dica  Sur.\nCorrespondencia:\nDr. Carlos A. Briones-Torres\nResidencia Patolog\u00eda Cl\u00ednica, M\u00e9dica Sur. Puente de Piedra, N\u00fam. 150, Col. Toriello Guerra. C.P. 14050, M\u00e9xico, D.F.\nCorreo electr\u00f3nico: carloandrebt@gmail.comCarlo A. Briones-Torres,* Juan A. Echeverr\u00eda-Vargas,**\nGuillermo S. Garc\u00eda-Ramos,*** V\u00edctor Noffal-Nu\u00f1o,* Jos\u00e9 P\u00e9rez-J\u00e1uregui*\nRev Invest Med Sur Mex, Julio-Septiembre 2014; 21 (3): 116-119ART\u00cdCULO ORIGINAL\nABSTRACTABSTRACTABSTRACTABSTRACTABSTRACT\nIntroduction. Introduction. Introduction. Introduction. Introduction. The gold standard for diagnosis of neurodegenera-\ntive diseases of undetermined origin is brain biopsy; however, newtechniques have been developed that supports its diagnosis. Thedetection of protein markers in cerebrospinal fluid, such as 14-3-3protein, and Tau protein is vital for diagnosis. Objective.Objective.Objective.Objective.Objective. Deter-\nmine the relationship between 14-3-3 and Tau testing in patientsreferred to the Laboratory of Clinical Pathology with a probablediagnosis of neurodegenerative diseases associated with undeter-mined origin. Material and methods.Material and methods.Material and methods.Material and methods.Material and methods. It was conducted a retros-\npective observational-search using the database of the informationsystem of the Laboratory of Clinical Pathology Medical Sur fromJanuary 2008 through December 2013 for all requested tests of 14-3-3 and tau Protein in cerebrospinal fluid. Results.Results.Results.Results.Results. Forty-two of 89\nrequested tests were positive (14-3-3) (47.2%) of which 69% werewomen with a mean age of 55.7 years (29-73). 31% were men witha mean age of 59.76 (36-72). The average value of the Tau proteinin the positive patients was 9,640 pg/mL (SD \u00b1 18,184 pg/mL).\nDiscussion.Discussion.Discussion.Discussion.Discussion. In Mexico there is no well-documented information\nabout incidence of these diseases, however, these biochemicalmarkers are very helpful by not being post-mortem procedures.\nThese markers can be elevated in vascular, neoplastic, inflamma-tory and metabolic diseases of the central nervous system, which areassociated with a rapid neuronal destruction. Conclusion.Conclusion.Conclusion.Conclusion.Conclusion. In the\ncontext of patients with dementia of undetermined origin, it shouldbe considered the detection of 14-3-3 and Tau protein, since itspresence is highly correlated with prion disease.\nKey words.Key words.Key words.Key words.Key words. 14-3-3 protein. Tau protein. Prions. Creutzfeldt-Jakob.RESUMENRESUMENRESUMENRESUMENRESUMEN\nIntroducci\u00f3n.Introducci\u00f3n.Introducci\u00f3n.Introducci\u00f3n.Introducci\u00f3n. La prueba de oro para el diagn\u00f3stico de las enfer-\nmedades neurodegenerativas de origen no determinado es la biop-sia cerebral; sin embargo, se han desarrollado nuevas t\u00e9cnicas queapoyan el diagn\u00f3stico de la misma. La detecci\u00f3n de marcadoresproteicos en l\u00edquido cefalorraqu\u00eddeo, como la prote\u00edna 14-3-3 y laprote\u00edna Tau, es de vital importancia para el diagn\u00f3stico. Objeti-Objeti-Objeti-Objeti-Objeti-\nvo.vo.vo.vo.vo. Determinar la relaci\u00f3n entre las pruebas de 14-3-3 y Tau en\npacientes referidos al Laboratorio de Patolog\u00eda Cl\u00ednica con un pro-bable diagn\u00f3stico asociado a enfermedades neurodegenerativasde origen no determinado. Material y m\u00e9todos.Material y m\u00e9todos.Material y m\u00e9todos.Material y m\u00e9todos.Material y m\u00e9todos. Se llev\u00f3 a cabo\nuna b\u00fasqueda retrospectiva-observacional, usando la base de da-tos del sistema de informaci\u00f3n del Laboratorio de Patolog\u00eda Cl\u00ednicade M\u00e9dica Sur de enero 2008 hasta diciembre 2013 de todas laspruebas solicitadas de las prote\u00ednas 14-3-3 y Tau en l\u00edquido cefalo-rraqu\u00eddeo. Resultados.Resultados.Resultados.Resultados.Resultados. De 89 pruebas solicitadas 42 resultaron\npositivas (prote\u00edna 14-3-3) (47.2%), de las cuales 69% correspon-dieron a mujeres con un promedio de edad de 55.7 a\u00f1os (29-73).El 31% correspondi\u00f3 a hombres con un promedio de edad de 59.76(36-72). El valor promedio de la prote\u00edna Tau en los pacientespositivos fue de 9,640 pg/mL (SD \u00b1 18,184 pg/mL). Discusi\u00f3n.Discusi\u00f3n.Discusi\u00f3n.Discusi\u00f3n.Discusi\u00f3n.\nEn M\u00e9xico no existe documentaci\u00f3n sobre la incidencia de estasenfermedades, pero los marcadores bioqu\u00edmicos son de gran ayudaal no ser procedimientos post-mortem.  Estos marcadores se pueden\nelevar en enfermedades vasculares, neopl\u00e1sicas, inflamatorias ymetab\u00f3licas del sistema nervioso central, adem\u00e1s de que se aso-cian con destrucci\u00f3n neuronal r\u00e1pida. Conclusi\u00f3n.\nConclusi\u00f3n.Conclusi\u00f3n.Conclusi\u00f3n.Conclusi\u00f3n. En el contexto\nde pacientes con demencia de origen no determinado se debetomar en consideraci\u00f3n la detecci\u00f3n de prote\u00edna 14-3-3 y Tau, yaque su presencia se correlaciona altamente con enfermedad porpriones.\nPalabras clave.Palabras clave.Palabras clave.Palabras clave.Palabras clave. Prote\u00edna 14-3-3. Prote\u00edna Tau. Priones. Creu-\ntzfeldt-Jakob.117 Rev Invest Med Sur Mex,  2014; 21 (3): 116-119Briones-Torres CA, et al.\nOOOOOOOOOOOOOOOOOO\nOO\nOO\nOO\nOO\nOO\nOO\nOO\nOO\nOO\nOO\nOO\nOO\nOO\nOO\nOO\nOOO\nOO\nOO\nOO\nOO\nOO\nOO\nOO\nOO\nOO\nOO\nOO\nOO\nOO\nOO\nOO\nOOO\nOO\nOO\nOO\nOO\nOO\nOO\nOO\nOO\nOO\nOO\nOO\nOO\nOO\nOO\nOO\nOOO\nOO\nOO\nOO\nOO\nOO\nOO\nOO\nOO\nOO\nOO\nOO\nOO\nOO\nOO\nOO\nOOO\nOO\nOO\nOO\nOO\nOO\nOO\nOO\nOO\nOO\nOO\nOO\nOO\nOO\nOO\nOO\nOOO\nOO\nOO\nOO\nOO\nOO\nOO\nOO\nOO\nOO\nOO\nOO\nOO\nOO\nOO\nOO\nOOO\nOO\nOO\nOO\nOO\nOO\nOO\nOO\nOO\nOO\nOO\nOO\nOO\nOO\nOO\nOO\nOOO\nOO\nOO\nOO\nOO\nOO\nOO\nOO\nOO\nOO\nOO\nOO\nOO\nOO\nOO\nOO\nOOO\nOO\nOO\nOO\nOO\nOO\nOO\nOO\nOO\nOO\nOO\nOO\nOO\nOO\nOO\nOO\nOOO\nOO\nOO\nOO\nOO\nOO\nOO\nOO\nOO\nOO\nOO\nOO\nOO\nOO\nOO\nOO\nOOO\nOO\nOO\nOO\nOO\nOO\nOO\nOO\nOO\nOO\nOO\nOO\nOO\nOO\nOO\nOO\nOOO\nOO\nOO\nOO\nOO\nOO\nOO\nOO\nOO\nOO\nOO\nOO\nOO\nOO\nOO\nOO\nOOO\nOO\nOO\nOO\nOO\nOO\nOO\nOO\nOO\nOO\nOO\nOO\nOO\nOO\nOO\nOO\nOOO\nOO\nOO\nOO\nOO\nOO\nOO\nOO\nOO\nOO\nOO\nOO\nOO\nOO\nOO\nOO\nOOO\nOO\nOO\nOO\nOO\nOO\nOO\nOO\nOO\nOO\nOO\nOO\nOO\nOO\nOO\nOO\nOOO\nOO\nOO\nOO\nOO\nOO\nOO\nOO\nOO\nOO\nOO\nOO\nOO\nOO\nOO\nOO\nOOO\nOO\nOO\nOO\nOO\nOO\nOO\nOO\nOO\nOO\nOO\nOO\nOO\nOO\nOO\nOO\nOOO\nOO\nOO\nOO\nOO\nOO\nOO\nOO\nOO\nOO\nOO\nOO\nOO\nOO\nOO\nOO\nOOO\nOO\nOO\nOO\nOO\nOO\nOO\nOO\nOO\nOO\nOO\nOO\nOO\nOO\nOO\nOO\nOOO\nOO\nOO\nOO\nOO\nOO\nOO\nOO\nOO\nOO\nOO\nOO\nOO\nOO\nOO\nOO\nOOO\nOO\nOO\nOO\nOO\nOO\nOO\nOO\nOO\nOO\nOO\nOO\nOO\nOO\nOO\nOO\nOOO\nOO\nOO\nOO\nOO\nOO\nOO\nOO\nOO\nOO\nOO\nOO\nOO\nOO\nOO\nOO\nOOO\nOO\nOO\nOO\nOO\nOO\nOO\nOO\nOO\nOO\nOO\nOO\nOO\nOO\nOO\nOO\nOOO\nOO\nOO\nOO\nOO\nOO\nOO\nOO\nOO\nOO\nOO\nOO\nOO\nOO\nOO\nOO\nOOO\nOO\nOO\nOO\nOO\nOO\nOO\nOO\nOO\nOO\nOO\nOO\nOO\nOO\nOO\nOO\nOOO\nOO\nOO\nOO\nOO\nOO\nOO\nOO\nOO\nOO\nOO\nOO\nOO\nOO\nOO\nOO\nOOO\nOO\nOO\nOO\nOO\nOO\nOO\nOO\nOO\nOO\nOO\nOO\nOO\nOO\nOO\nOO\nOOO\nOO\nOO\nOO\nOO\nOO\nOO\nOO\nOO\nOO\nOO\nOO\nOO\nOO\nOO\nOO\nOOO\nOO\nOO\nOO\nOO\nOO\nOO\nOO\nOO\nOO\nOO\nOO\nOO\nOO\nOO\nOO\nOOO\nOO\nOO\nOO\nOO\nOO\nOO\nOO\nOO\nOO\nOO\nOO\nOO\nOO\nOO\nOO\nOOO\nOO\nOO\nOO\nOO\nOO\nOO\nOO\nOO\nOO\nOO\nOO\nOO\nOO\nOO\nOO\nOOO\nOO\nOO\nOO\nOO\nOO\nOO\nOO\nOO\nOO\nOO\nOO\nOO\nOO\nOO\nOO\nOOO\nOO\nOO\nOO\nOO\nOO\nOO\nOO\nOO\nOO\nOO\nOO\nOO\nOO\nOO\nOO\nOOO\nOO\nOO\nOO\nOO\nOO\nOO\nOO\nOO\nOO\nOO\nOO\nOO\nOO\nOO\nOO\nOOO\nOO\nOO\nOO\nOO\nOO\nOO\nOO\nOO\nOO\nOO\nOO\nOO\nOO\nOO\nOO\nOOO\nOO\nOO\nOO\nOO\nOO\nOO\nOO\nOO\nOO\nOO\nOO\nOO\nOO\nOO\nOO\nOOO\nOO\nOO\nOO\nOO\nOO\nOO\nOO\nOO\nOO\nOO\nOO\nOO\nOO\nOO\nOO\nOOO\nOO\nOO\nOO\nOO\nOO\nOO\nOO\nOO\nOO\nOO\nOO\nOO\nOO\nOO\nOO\nOOO\nOO\nOO\nOO\nOO\nOO\nOO\nOO\nOO\nOO\nOO\nOO\nOO\nOO\nOO\nOO\nOOO\nOO\nOO\nOO\nOO\nOO\nOO\nOO\nOO\nOO\nOO\nOO\nOO\nOO\nOO\nOO\nOOO\nOO\nOO\nOO\nOO\nOO\nOO\nOO\nOO\nOO\nOO\nOO\nOO\nOO\nOO\nOO\nOOO\nOO\nOO\nOO\nOO\nOO\nOO\nOO\nOO\nOO\nOO\nOO\nOO\nOO\nOO\nOO\nOOO\nOO\nOO\nOO\nOO\nOO\nOO\nOO\nOO\nOO\nOO\nOO\nOO\nOO\nOO\nOO\nOOO\nOO\nOO\nOO\nOO\nOO\nOO\nOO\nOO\nOO\nOO\nOO\nOO\nOO\nOO\nOO\nOOO\nOO\nOO\nOO\nOO\nOO\nOO\nOO\nOO\nOO\nOO\nOO\nOO\nOO\nOO\nOO\nOOO\nOO\nOO\nOO\nOO\nOO\nOO\nOO\nOO\nOO\nOO\nOO\nOO\nOO\nOO\nOO\nOOO\nOO\nOO\nOO\nOO\nOO\nOO\nOO\nOO\nOO\nOO\nOO\nOO\nOO\nOO\nOO\nOOO\nOO\nOO\nOO\nOO\nOO\nOO\nOO\nOO\nOO\nOO\nOO\nOO\nOO\nOO\nOO\nOOO\nOO\nOO\nOO\nOO\nOO\nOO\nOO\nOO\nOO\nOO\nOO\nOO\nOO\nOO\nOO\nOOO\nOO\nOO\nOO\nOO\nOO\nOO\nOO\nOO\nOO\nOO\nOO\nOO\nOO\nOO\nOO\nOOO\nOO\nOO\nOO\nOO\nOO\nOO\nOO\nOO\nOO\nOO\nOO\nOO\nOO\nOO\nOO\nOOO\nOO\nOO\nOO\nOO\nOO\nOO\nOO\nOO\nOO\nOO\nOO\nOO\nOO\nOO\nOO\nOOO\nOO\nOO\nOO\nOO\nOO\nOO\nOO\nOO\nOO\nOO\nOO\nOO\nOO\nOO\nOO\nOOO\nOO\nOO\nOO\nOO\nOO\nOO\nOO\nOO\nOO\nOO\nOO\nOO\nOO\nOO\nOO\nOOO\nOO\nOO\nOO\nOO\nOO\nOO\nOO\nOO\nOO\nOO\nOO\nOO\nOO\nOO\nOO\nOOO\nOO\nOO\nOO\nOO\nOO\nOO\nOO\nOO\nOO\nOO\nOO\nOO\nOO\nOO\nOO\nOO\nOOOOOOOOOOOOOOOOOO\nOO\nOO\nOO\nOO\nOO\nOO\nOO\nOO\nOO\nOO\nOO\nOO\nOO\nOO\nOO\nOOO\nOO\nOO\nOO\nOO\nOO\nOO\nOO\nOO\nOO\nOO\nOO\nOO\nOO\nOO\nOO\nOOO\nOO\nOO\nOO\nOO\nOO\nOO\nOO\nOO\nOO\nOO\nOO\nOO\nOO\nOO\nOO\nOOO\nOO\nOO\nOO\nOO\nOO\nOO\nOO\nOO\nOO\nOO\nOO\nOO\nOO\nOO\nOO\nOOO\nOO\nOO\nOO\nOO\nOO\nOO\nOO\nOO\nOO\nOO\nOO\nOO\nOO\nOO\nOO\nOOO\nOO\nOO\nOO\nOO\nOO\nOO\nOO\nOO\nOO\nOO\nOO\nOO\nOO\nOO\nOO\nOOO\nOO\nOO\nOO\nOO\nOO\nOO\nOO\nOO\nOO\nOO\nOO\nOO\nOO\nOO\nOO\nOOO\nOO\nOO\nOO\nOO\nOO\nOO\nOO\nOO\nOO\nOO\nOO\nOO\nOO\nOO\nOO\nOOO\nOO\nOO\nOO\nOO\nOO\nOO\nOO\nOO\nOO\nOO\nOO\nOO\nOO\nOO\nOO\nOOO\nOO\nOO\nOO\nOO\nOO\nOO\nOO\nOO\nOO\nOO\nOO\nOO\nOO\nOO\nOO\nOOO\nOO\nOO\nOO\nOO\nOO\nOO\nOO\nOO\nOO\nOO\nOO\nOO\nOO\nOO\nOO\nOOO\nOO\nOO\nOO\nOO\nOO\nOO\nOO\nOO\nOO\nOO\nOO\nOO\nOO\nOO\nOO\nOOO\nOO\nOO\nOO\nOO\nOO\nOO\nOO\nOO\nOO\nOO\nOO\nOO\nOO\nOO\nOO\nOOO\nOO\nOO\nOO\nOO\nOO\nOO\nOO\nOO\nOO\nOO\nOO\nOO\nOO\nOO\nOO\nOOO\nOO\nOO\nOO\nOO\nOO\nOO\nOO\nOO\nOO\nOO\nOO\nOO\nOO\nOO\nOO\nOOO\nOO\nOO\nOO\nOO\nOO\nOO\nOO\nOO\nOO\nOO\nOO\nOO\nOO\nOO\nOO\nOOO\nOO\nOO\nOO\nOO\nOO\nOO\nOO\nOO\nOO\nOO\nOO\nOO\nOO\nOO\nOO\nOOO\nOO\nOO\nOO\nOO\nOO\nOO\nOO\nOO\nOO\nOO\nOO\nOO\nOO\nOO\nOO\nOOO\nOO\nOO\nOO\nOO\nOO\nOO\nOO\nOO\nOO\nOO\nOO\nOO\nOO\nOO\nOO\nOOO\nOO\nOO\nOO\nOO\nOO\nOO\nOO\nOO\nOO\nOO\nOO\nOO\nOO\nOO\nOO\nOOO\nOO\nOO\nOO\nOO\nOO\nOO\nOO\nOO\nOO\nOO\nOO\nOO\nOO\nOO\nOO\nOOO\nOO\nOO\nOO\nOO\nOO\nOO\nOO\nOO\nOO\nOO\nOO\nOO\nOO\nOO\nOO\nOOO\nOO\nOO\nOO\nOO\nOO\nOO\nOO\nOO\nOO\nOO\nOO\nOO\nOO\nOO\nOO\nOOO\nOO\nOO\nOO\nOO\nOO\nOO\nOO\nOO\nOO\nOO\nOO\nOO\nOO\nOO\nOO\nOOO\nOO\nOO\nOO\nOO\nOO\nOO\nOO\nOO\nOO\nOO\nOO\nOO\nOO\nOO\nOO\nOOO\nOO\nOO\nOO\nOO\nOO\nOO\nOO\nOO\nOO\nOO\nOO\nOO\nOO\nOO\nOO\nOO\nOOOOOOOOOOOOOOOOOO\nOO\nOO\nOO\nOO\nOO\nOO\nOO\nOO\nOO\nOO\nOO\nOO\nOO\nOO\nOO\nOOO\nOO\nOO\nOO\nOO\nOO\nOO\nOO\nOO\nOO\nOO\nOO\nOO\nOO\nOO\nOO\nOOO\nOO\nOO\nOO\nOO\nOO\nOO\nOO\nOO\nOO\nOO\nOO\nOO\nOO\nOO\nOO\nOOO\nOO\nOO\nOO\nOO\nOO\nOO\nOO\nOO\nOO\nOO\nOO\nOO\nOO\nOO\nOO\nOOO\nOO\nOO\nOO\nOO\nOO\nOO\nOO\nOO\nOO\nOO\nOO\nOO\nOO\nOO\nOO\nOOO\nOO\nOO\nOO\nOO\nOO\nOO\nOO\nOO\nOO\nOO\nOO\nOO\nOO\nOO\nOO\nOOO\nOO\nOO\nOO\nOO\nOO\nOO\nOO\nOO\nOO\nOO\nOO\nOO\nOO\nOO\nOO\nOOO\nOO\nOO\nOO\nOO\nOO\nOO\nOO\nOO\nOO\nOO\nOO\nOO\nOO\nOO\nOO\nOOO\nOO\nOO\nOO\nOO\nOO\nOO\nOO\nOO\nOO\nOO\nOO\nOO\nOO\nOO\nOO\nOOO\nOO\nOO\nOO\nOO\nOO\nOO\nOO\nOO\nOO\nOO\nOO\nOO\nOO\nOO\nOO\nOOO\nOO\nOO\nOO\nOO\nOO\nOO\nOO\nOO\nOO\nOO\nOO\nOO\nOO\nOO\nOO\nOOO\nOO\nOO\nOO\nOO\nOO\nOO\nOO\nOO\nOO\nOO\nOO\nOO\nOO\nOO\nOO\nOOO\nOO\nOO\nOO\nOO\nOO\nOO\nOO\nOO\nOO\nOO\nOO\nOO\nOO\nOO\nOO\nOOO\nOO\nOO\nOO\nOO\nOO\nOO\nOO\nOO\nOO\nOO\nOO\nOO\nOO\nOO\nOO\nOOO\nOO\nOO\nOO\nOO\nOO\nOO\nOO\nOO\nOO\nOO\nOO\nOO\nOO\nOO\nOO\nOOO\nOO\nOO\nOO\nOO\nOO\nOO\nOO\nOO\nOO\nOO\nOO\nOO\nOO\nOO\nOO\nOOO\nOO\nOO\nOO\nOO\nOO\nOO\nOO\nOO\nOO\nOO\nOO\nOO\nOO\nOO\nOO\nOOO\nOO\nOO\nOO\nOO\nOO\nOO\nOO\nOO\nOO\nOO\nOO\nOO\nOO\nOO\nOO\nOOO\nOO\nOO\nOO\nOO\nOO\nOO\nOO\nOO\nOO\nOO\nOO\nOO\nOO\nOO\nOO\nOOO\nOO\nOO\nOO\nOO\nOO\nOO\nOO\nOO\nOO\nOO\nOO\nOO\nOO\nOO\nOO\nOOO\nOO\nOO\nOO\nOO\nOO\nOO\nOO\nOO\nOO\nOO\nOO\nOO\nOO\nOO\nOO\nOOO\nOO\nOO\nOO\nOO\nOO\nOO\nOO\nOO\nOO\nOO\nOO\nOO\nOO\nOO\nOO\nOOO\nOO\nOO\nOO\nOO\nOO\nOO\nOO\nOO\nOO\nOO\nOO\nOO\nOO\nOO\nOO\nOOO\nOO\nOO\nOO\nOO\nOO\nOO\nOO\nOO\nOO\nOO\nOO\nOO\nOO\nOO\nOO\nOOOOOOOOOOOOOOOOOOA (n = 89)\nB (n = 42)C (n =39)\n(X = 9,640 pg/mL)INTRODUCCI\u00d3N\nLas enfermedades por priones forman parte del es-\npectro de enfermedades neurodegenerativas de origen nodeterminado, en humanos se han reconocido cinco, entreellas: enfermedad de Creutzfeldt-Jakob (ECJ),\n1 s\u00edndrome\nGerstmann-Straussler-Scheinker e insomnia familiar letal.2\nLa biopsia cerebral contin\u00faa siendo la prueba de oro parael diagn\u00f3stico de estos padecimientos; sin embargo, enlos \u00faltimos a\u00f1os se han desarrollado nuevas t\u00e9cnicas nopost-mortem  que han apoyado cl\u00ednicamente su diagn\u00f3sti-\nco.\nEl Centro para Control y Prevenci\u00f3n de Enfermedades\n(CDC) ha propuesto los siguientes criterios para el diag-n\u00f3stico de la enfermedad de Creutzfeldt-Jakob:\n3\n\u2022 Demencia progresiva.\u2022 Al menos dos de cuatro caracter\u00edsticas cl\u00ednicas (mio-\nclonus, alteraciones visuales o cerebelosas, alteraci\u00f3npiramidal/extrapiramidal, mutismo acin\u00e9tico).\n\u2022 Electroencefalograma at\u00edpico, y/o una prueba de pro-\nte\u00edna 14-3-3 positivo en l\u00edquido cefalorraqu\u00eddeo (LCR),y/o una imagen por resonancia magn\u00e9tica con altera-ciones en el n\u00facleo caudado y/o putamen.\n\u2022 Falta de evidencia de diagn\u00f3sticos alternativos.\nLa prote\u00edna 14-3-3, una enolasa, act\u00faa como modula-\ndora de la fosforilaci\u00f3n de prote\u00ednas. La detecci\u00f3n de laprote\u00edna 14-3-3 en LCR es indicativa de una destrucci\u00f3nneuronal sustancial y relativamente r\u00e1pida. El principaluso cl\u00ednico de la medici\u00f3n de esta prote\u00edna es el diagn\u00f3s-tico diferencial de demencia, tanto con la enfermedad deAlzheimer, como con la demencia progresiva multi-infar-to, las cuales no se relacionan con un incremento en losniveles de prote\u00edna 14-3-3. En 2012 la Academia Ameri-cana de Neurolog\u00eda llev\u00f3 a cabo una revisi\u00f3n sistem\u00e1ticaque report\u00f3 una sensibilidad de 92% y una especificidadde 80% para la prote\u00edna 14-3-3 en el diagn\u00f3stico de laECJ.\n4 Una concentraci\u00f3n de prote\u00edna 14-3-3 > 1.5 ng/mL\napoya el diagn\u00f3stico de ECJ.5,6 A pesar de la sensibilidad\ny especificidad que tiene esta prueba, se pueden presen-tar resultados falsos positivos en pacientes con encefalo-pat\u00eda de origen viral, metab\u00f3lica, met\u00e1stasis cerebrales,entre otras.\nSi bien la prote\u00edna Tau se ha estudiado m\u00e1s en la en-\nfermedad de Alzheimer, existe similitud desde una pers-pectiva neuropatol\u00f3gica entre esta enfermedad y la ECJ.\n7\nAlgunos estudios han demostrado que la prote\u00edna Tau pre-senta mayor precisi\u00f3n y especificidad en comparaci\u00f3n conla prote\u00edna 14-3-3.\n8 Sin embargo, la combinaci\u00f3n de es-tos estudios es superior a solamente realizar la medici\u00f3n\nde prote\u00edna 14-3-3, pero aparentemente esta combina-ci\u00f3n no es superior a realizar solamente la medici\u00f3n deprote\u00edna Tau.\n9 Uno de los inconvenientes de la prote\u00edna\nTau es la alta tasa de resultados falsos negativos y falsospositivos.\n9\nOBJETIVO\nEl objetivo es describir lo observado en las pruebas\npara las prote\u00ednas 14-3-3 y Tau en pacientes referidos alLaboratorio de Patolog\u00eda Cl\u00ednica con un probable diag-n\u00f3stico asociado a enfermedades neurodegenerativas deorigen no determinado.\nMATERIAL Y M\u00c9TODOS\nSe realiz\u00f3 una b\u00fasqueda retrospectiva-observacional\nusando la base de datos del sistema de informaci\u00f3n delLaboratorio de Patolog\u00eda Cl\u00ednica de M\u00e9dica Sur desdeenero 2008 hasta diciembre 2013 de todas las pruebassolicitadas. Los resultados obtenidos del laboratorio dereferencia, donde se realiza esta prueba, constan de in-munoensayos en l\u00edquido cefalorraqu\u00eddeo para la cuantifi-caci\u00f3n y detecci\u00f3n de Tau y 14-3-3, respectivamente. Elan\u00e1lisis estad\u00edstico se realiz\u00f3 mediante el programa ExcelOffice Microsoft.\nRESULTADOS\nEn este periodo se solicitaron al Laboratorio de Patolo-\ng\u00eda Cl\u00ednica un total de 89 estudios para las prote\u00ednas 14-3-3 y Tau. De estos casos, 42 resultaron positivos para la\nFigura 1.  Resultados del an\u00e1lisis. A. N\u00famero de pruebas solicita-\ndas. B. Pacientes positivos para prote\u00ednas 14.3.3. C. Pacientes\ncon prote\u00edna Tau por arriba de los valores de referencia. D. Pa-\ncientes con prote\u00edna Tau en valores normales.Frecuencia90\n80\n70\n6050\n40\n30\n20\n10\n0Solicitadas 14-3-3 Tau\nPositivasD (n = 3)(X = 472 pg/mL)118 Rev Invest Med Sur Mex,  2014; 21 (3): 116-119Prote\u00ednas 14-3-3 y Tau como biomarcadores en  enfermedades neurodegenerativas.\n/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15\n/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15\n/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15/i15\n/i15\nprote\u00edna 14-3-3 y 39 de \u00e9stos para la prote\u00edna Tau, en la\ncual se obtuvo un valor por encima de los intervalos dereferencia (0-1,150 pg/mL) con un promedio de 9,640 pg/mL. En los tres estudios restantes, en donde se obtuvouna prote\u00edna 14-3-3 positiva, los valores de Tau se encon-traron en los l\u00edmites normales con un promedio de 472pg/mL (Figura 1). El 69% de los casos fueron mujeres y31% hombres (Figura 2). En cuanto a las edades, en mu-jeres se observaron rangos de 29-73 a\u00f1os (X = 55.7) y enhombres de 36-72 a\u00f1os (X = 59.7) (Figura 3).\nDISCUSI\u00d3N\nEn M\u00e9xico no est\u00e1 bien documentada la incidencia de\nestas enfermedades por lo complicado del diagn\u00f3stico.La edad promedio en el estudio fue de 57 a\u00f1os, con unrango de edad de 29-73 a\u00f1os, similar a Vel\u00e1zquez-P\u00e9rez,et al.,\n10 quienes reportaron un rango de presentaci\u00f3n de\nla ECJ en poblaci\u00f3n mexicana de 23-75 a\u00f1os. La presen-taci\u00f3n de la ECJ en M\u00e9xico incluye a la poblaci\u00f3n joven,lo cual difiere con otros tipos de poblaciones.\n11 Sin em-\nbargo, se observ\u00f3 una diferencia importante en la fre-cuencia entre g\u00e9neros, con 69% en mujeres y 31% enhombres, lo cual no concuerda con lo reportado en laliteratura, ya que aparentemente no existe una predilec-ci\u00f3n de g\u00e9nero. Sin embargo, Vel\u00e1zquez-P\u00e9rez, et al.\n10 y\nOlov, et al.12 reportaron una frecuencia de la ECJ similar\nentre g\u00e9neros.\nEstos marcadores bioqu\u00edmicos son de gran ayuda para\nllegar al diagn\u00f3stico ya que no son procedimientos post-\nmortem. Un resultado negativo no excluye el diagn\u00f3stico\nde estas enfermedades, mientras que resultados positivosse pueden observar en otro tipo de enfermedades, porejemplo, en encefalitis por herpes simple, encefalopat\u00edahip\u00f3xico-isqu\u00e9mica, met\u00e1stasis a SNC, encefalopat\u00edasmetab\u00f3licas y enfermedad vascular cerebral, entre otras.Por lo que se sugiere a la prote\u00edna 14-3-3 un marcador de\nmuerte celular cerebral m\u00e1s que de la ECJ.\n13 Otra deter-\nminante de los niveles de prote\u00edna 14-3-3 es la heteroge-neidad molecular de la ECJ, donde la sensibilidad de laprueba ha sido mayor en subtipos cl\u00e1sicos de la enferme-dad y baja en subtipos no cl\u00e1sicos.\n14,15\nLa limitaci\u00f3n del presente estudio radica en no cono-\ncer el desenlace final de los pacientes, ya que pertenecena diversas instituciones p\u00fablicas y privadas, lo que compli-ca el posible seguimiento de estos pacientes.\nCONCLUSI\u00d3N\nEn el contexto de pacientes con demencia de origen\nno determinado se debe tomar en consideraci\u00f3n la detec-ci\u00f3n de las prote\u00ednas 14-3-3 y Tau, ya que su presencia secorrelaciona altamente con la enfermedad por priones.Se debe considerar que es una herramienta relativamen-te sencilla de solicitar, la cual aporta al cl\u00ednico gran infor-maci\u00f3n para el pron\u00f3stico de su paciente, con el benefi-cio de no ser un procedimiento post-mortem.\nABREVIATURAS\n\u2022CDC:CDC:CDC:CDC:CDC: Centro para Control y Prevenci\u00f3n de Enferme-\ndades.\n\u2022ECJ:ECJ:ECJ:ECJ:ECJ: enfermedad Creuztfeldt-Jakob.\n\u2022LCR:LCR:LCR:LCR:LCR: l\u00edquido cefalorraqu\u00eddeo.\n\u2022SNC:SNC:SNC:SNC:SNC: sistema nervioso central.\nREFERENCIASREFERENCIASREFERENCIASREFERENCIASREFERENCIAS\n1. Collins SJ, Sanchez-Juan P, Masters CL, et al. Determinants of\ndiagnostic investigations sensivities across the clinical spectrumof sporadic Creutzfeldt-Jakob disease. Brain 2006; 129: 2278.\n2. Puoti G, Bizzi A, Forloni G, et al. Sporadic human prion diseases:\nmolecular insights and diagnosis. Lancet Neurol 2012; 11: 618.\n3. CDC\u2019s Diagnostic Criteria for Creutzfeldt-Jakob Disease (CJD), 2010.Figura 2.Figura 2.Figura 2.Figura 2.Figura 2. Frecuencia entre hombres y mujeres.Frecuencia30\n25201510\n50\nFemenino Masculino\nFigura 3.Figura 3.Figura 3.Figura 3.Figura 3. Frecuencia de presentaci\u00f3n dependiendo de la edad.Frecuencia18\n161412\n10\n864\n2\n0\n< 40 40-60 > 60\nA\u00f1os27 (69%)\n13 (31%)\n717 18119 Rev Invest Med Sur Mex,  2014; 21 (3): 116-119Briones-Torres CA, et al.\n4. Muayqil T, Gronseth G, Camicioli R. Evidence-based guideline:\ndiagnostic accuracy of CSF 14-3-3 protein in sporadic Creutzfel-dt-Jakob disease: report of the guideline development subcom-mittee of the American Academy of Neurology. Neurology 2012;\n79: 1499.\n5. Collins S, Boyd A, Fletcher A, et al. Creutzfeldt-Jakob disease:\ndiagnostic utility of 14-3-3 inmunodetection in cerebrospinalfluid. J Clin Neurosci 2000; 7: 203-8.\n6. Preissner CM, Aksamit AJ, Parisi JE, Grebe SK. Development and\nvalidation of an immunochemiluminometric assay for 14-3-3protein. Clin Chem 2009; 55(S6): A199; abstract D-149.\n7. Otto M, Wiltfang J, Tumani H, et al. Elevated levels of tau pro-\ntein in cerebrospinal fluid of patients with Creutzfeldt-Jakob di-sease. Neurosci Lett 1997; 225: 210-2.\n8. Otto M, Wiltfang J, Cepek L, et al. Tau protein and 14-3-3\nprotein in the differential diagnosis of Creutzfeldt-Jakob disease.Neurology 2002; 58: 192-7.\n9. Hamlin C, Puoti G, Berri S, et al. A comparison of tau protein and\n14-3-3 protein in the diagnosis of Creutzfeldt-Jakob disease.Neurology 2012; 79: 547-51.10. Vel\u00e1squez-P\u00e9rez L, Rembao-Bojorquez D, Guevara J, et al. Creu-\ntzfeldt-Jakob disease in Mexico. Neuropathology 2007; 27: 419-\n28.\n11. Bateman D, Hilton D, Love S, Zeidler M, Collinge J. Sporadic\nCreutzfeldt-Jakob disease in a 18 year old in the UK. Lancet\n1995; 346: 1155.\n12. Olov PL. Creuztfeldt-Jakob disease in Sweden.  J Neurol Neuro-\nsurg Psychiatry 1998; 65: 836-41.\n13. Satoh J, Kuruhara K, Yukitake M, Kuroda Y. The 14-3-3\nprotein detectable in the cerebrospinal fluid in patients withprion-unrelated neurological diseases is expressed constitu-tively in neurons and glial cells in culture. Eur Neurol  1999;\n41: 216.\n14. Collins SJ, Sanchez-Juan P, Masters CL, et al. Determinants of\ndiagnostic investigation sensitivities across the clinical spec-trum of sporadic Creutzfeldt-Jakob disease. Brain 2006; 129:\n2278.\n15. Kransnianski A, Schulz-Schaeffer WJ, Kallenberg K, et al. Clini-\ncal findings and diagnostic tests in the MV2 subtype of sporadicCJD. Brain  2006; 129: 2288.\n\u00d3rgano de Difusi\u00f3n de\nla Sociedad de M\u00e9dicosRevista de\nInvestigaci\u00f3n", "language": "PDF", "image": "PDF", "pagetype": "PDF", "links": "PDF"}